Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Starlake Bioscience Co Inc Zhaoqing Guangdong stock ¥11.29, price ¥4.28, upside +163.8%, quality 41 out of 100. Rating: strongly undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range ¥3.53 – ¥8.49 · fair‑value band ¥8.01 – ¥14.58 · the ¥4.28 price screens below the ¥11.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Starlake Bioscience Co Inc Zhaoqing Guangdong in your weekly email
Every Wednesday you see whether Starlake Bioscience Co Inc Zhaoqing Guangdong is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Star Lake Bioscience Co., Inc. Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally.
Show moreShow less
The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an intermediate for food and pharmaceutical raw material; adefovir dipivoxil tablets used to reduce the activity of HBV DNA polymerase and anti-virus by destroying Hepatitis B virus DNA; and L-threonine that is used in premixtures, and pig and poultry feed.
It also provides disodium 5'-ribonucleotide to cure chronic hepatitis, muscular atrophy, and eye diseases; disodium 5-inosinate to cure leukopenia, thrombocytopenia, and chronic and acute hepatitis; and inosine, which is used for the treatment of chronic and acute hepatitis, heart disease, leukopenia or thrombocytopenia, central choroidoretinitis, etc.
In addition, the company offers disodium 5'-guanylate for canned and salted meat, ham, etc. Further, it provides ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, L-threonine, L-lysine, etc.
Star Lake Bioscience Co., Inc. Zhaoqing Guangdong was founded in 1964 and is based in Zhaoqing, China.
Stock analysis
Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) currently trades at ¥4.28, while our model-based Fair Value estimate is ¥11.29, implying the stock looks roughly 62% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥15.61 per share, and 15 of the 16 models we run sit above the ¥4.28 price.
Bear case: the Asset-Based group reads lowest at ¥3.04, and 1 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥8.01 (bear) to ¥14.58 (bull), the price of ¥4.28 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 1999: revenue and profit before it include the divested business. Growth is measured afresh from 1999.
Starlake Bioscience Co Inc Zhaoqing Guangdong reported revenue of 15.9B CNY in FY2025 versus 4.1B CNY in FY2021, a compound +40.6%/yr. Reported net income was 979M CNY in FY2025, compounding +59.3%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 7.1B CNY (≈ $1.1B) Small · P/E ratio 32.9 · P/S ratio 0.45 · EPS (TTM) ¥0.1300 · Dividend yield 8.9% · Net margin 1.3% · Return on equity 2.7% · Return on assets (EBIT) 8.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 164%, 600866 screens cheaper than that median.
Fair Value models
Bear¥8.01Fair Value ¥11.29Bull¥14.58
Price ¥4.28 · Upside +163.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 1999: revenue and profit before it include the divested business. Growth is measured afresh from 1999.
Revenue growth 1 year
−8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+70.1%
Start year 2020 (pandemic). Over 10 years: +36.1% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+32.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+24.0%
Dividend (yield on the price)8.9%
Per share before 1999divided by the spin-off factor 1.0523
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 24.0% / 31.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 8%
Compare Starlake Bioscience Co Inc Zhaoqing Guangdong with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score41 · Below median
Fair Value upside+163.8% · Top 25%
Profitability
Return on equity (12 months)2.7% · Above median
Return on assets5.7% · Top 25%
Net margin (12 months)1.3% · Below median
Operating margin (12 months)4.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)8.0% · Above median
Dividend yield (12 months)8.9% · Top 25%
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Starlake Bioscience Co Inc Zhaoqing Guangdong Fair Value". https://www.fairvalue-calculator.com/stock/600866
Frequently asked questions
Is Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of ¥11.29 versus a price of ¥4.28, about +164% upside (undervalued).
What is the fair value of 600866?
Our model-based fair value for Starlake Bioscience Co Inc Zhaoqing Guangdong is ¥11.29 (as of Nov 4, 2026), built from audited fundamentals. The current price: ¥4.28.
What is the quality score of 600866?
Starlake Bioscience Co Inc Zhaoqing Guangdong has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
Our model-based price target is the fair value of ¥11.29 (as of Nov 4, 2026) from 16 valuation models. Cautious scenario ¥8.01, optimistic scenario ¥14.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Starlake Bioscience Co Inc Zhaoqing Guangdong stock forecast for 2026?
Our models put fair value at ¥11.29, about +164% upside versus a price of ¥4.28 (undervalued). Cautious scenario ¥8.01, optimistic scenario ¥14.58. The calculation is refreshed regularly with new filings.
What is the revenue of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
Starlake Bioscience Co Inc Zhaoqing Guangdong reported trailing-twelve-month revenue of about 15.9B CNY (latest available figure, as of Nov 4, 2026).
Does Starlake Bioscience Co Inc Zhaoqing Guangdong pay a dividend?
Starlake Bioscience Co Inc Zhaoqing Guangdong currently shows a dividend yield of 8.88% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) and when is the ex-dividend date?
Starlake Bioscience Co Inc Zhaoqing Guangdong pays a dividend of ¥0.38 per share a year, a dividend yield of 8.9%. The last ex-dividend date was Jul 23, 2026. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Starlake Bioscience Co Inc Zhaoqing Guangdong it is ¥11.29 per share (as of Nov 4, 2026), against a price of ¥4.28. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Starlake Bioscience Co Inc Zhaoqing Guangdong stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 600866 trades below its calculated fair value: price ¥4.28, fair value ¥11.29, a gap of about +164% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600866?
No. The price is what the market pays today (¥4.28); the fair value is what the company's own numbers justify (¥11.29). For Starlake Bioscience Co Inc Zhaoqing Guangdong the two are ¥7.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Starlake Bioscience Co Inc Zhaoqing Guangdong worth?
The market values Starlake Bioscience Co Inc Zhaoqing Guangdong at about 7.1B CNY (market capitalisation, as of Nov 4, 2026). Per share that is ¥4.28; our models calculate a fair value of ¥11.29 per share.
What do the bullish and bearish scenarios say about 600866?
Our models span a range for Starlake Bioscience Co Inc Zhaoqing Guangdong: cautious scenario ¥8.01, base ¥11.29, optimistic ¥14.58 per share (as of Nov 4, 2026, price ¥4.28). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 600866?
Starlake Bioscience Co Inc Zhaoqing Guangdong trades at a price-to-earnings ratio of 32.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥11.29 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 21.9. Other multiples: P/B 0.9, P/S 0.4, EV/EBITDA 6.3.
How solid is the balance sheet of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
Balance-sheet figures for Starlake Bioscience Co Inc Zhaoqing Guangdong (as of Nov 4, 2026): return on equity 2.7%, debt of 0.29 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 600866 from its 52-week high?
Starlake Bioscience Co Inc Zhaoqing Guangdong trades at ¥4.28, about 47% below its 52-week high of ¥8.13 and 7% above the low of ¥4.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.29 is for.
Which stocks are comparable to Starlake Bioscience Co Inc Zhaoqing Guangdong?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Starlake Bioscience Co Inc Zhaoqing Guangdong stock attractive at the current price?
The data as of Nov 4, 2026: price ¥4.28, calculated fair value ¥11.29 (+164%), Quality Score 41/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600866 calculated?
We run Starlake Bioscience Co Inc Zhaoqing Guangdong through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥11.29 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Starlake Bioscience Co Inc Zhaoqing Guangdong currently trades 62% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
The closing price on Nov 6, 2026 was ¥4.28. Our model-based fair value is ¥11.29, about +164% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Starlake Bioscience Co Inc Zhaoqing Guangdong right now?
The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (¥8.01). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥8.01 to ¥14.58) leaves room in how you read the outcome.
Key figures of Starlake Bioscience Co Inc Zhaoqing Guangdong
How large is the market capitalisation of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
The market capitalisation of Starlake Bioscience Co Inc Zhaoqing Guangdong is 7.1B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
The price-to-sales ratio of Starlake Bioscience Co Inc Zhaoqing Guangdong is 0.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
Earnings per share at Starlake Bioscience Co Inc Zhaoqing Guangdong are ¥0.1300 (price ÷ EPS = P/E 32.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
The dividend yield of Starlake Bioscience Co Inc Zhaoqing Guangdong is 8.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
The net margin of Starlake Bioscience Co Inc Zhaoqing Guangdong is 1.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
The return on equity (ROE) of Starlake Bioscience Co Inc Zhaoqing Guangdong is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
On an EBIT basis the return on assets of Starlake Bioscience Co Inc Zhaoqing Guangdong is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
The operating margin of Starlake Bioscience Co Inc Zhaoqing Guangdong is 4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
Revenue at Starlake Bioscience Co Inc Zhaoqing Guangdong is growing +8.0% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?
Earnings per share at Starlake Bioscience Co Inc Zhaoqing Guangdong are growing −67.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) generate?
The free cash flow of Starlake Bioscience Co Inc Zhaoqing Guangdong is −747M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) carry?
The net debt of Starlake Bioscience Co Inc Zhaoqing Guangdong is 3.1B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Starlake Bioscience Co Inc Zhaoqing Guangdong in the live analysis
One click puts Starlake Bioscience Co Inc Zhaoqing Guangdong on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026